Triple-positive breast cancer is usually not prone to recurrence. The so-called triple-positive breast cancer mainly refers to pathological immunohistochemistry results suggesting positive estrogen receptor, progesterone receptor and HER-2 receptor. During the clinical treatment of breast, if estrogen receptor and progesterone receptor are positive, endocrine therapy is usually used, which can effectively reduce the recurrence and metastasis of breast cancer, while if HER-2 receptor is positive, molecular targeted drugs, such as Herceptin, can be used, which can effectively reduce the metastasis and recurrence of breast cancer. Although breast cancer, as a malignant tumor, has the possibility of recurrence and metastasis, but if estrogen receptor, progesterone receptor and HER-2 receptor positive, then that patient can be treated with endocrine therapy as well as molecular targeted drugs, which can effectively reduce its recurrence and metastasis. Therefore, triple-positive breast cancer is treated and controlled by effective drugs and is relatively less prone to recurrence and metastasis.